{"id":2905,"date":"2024-01-03T05:54:43","date_gmt":"2024-01-03T13:54:43","guid":{"rendered":"https:\/\/depts.washington.edu\/tlcart\/?p=2905"},"modified":"2024-01-03T05:54:43","modified_gmt":"2024-01-03T13:54:43","slug":"tlc-art-featured-on-poz-com","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/tlcart\/tlc-art-featured-on-poz-com\/","title":{"rendered":"TLC-ART featured on POZ.com"},"content":{"rendered":"<p>Prof. Ho&#8217;s Laboratory is featured on <em>POZ.com<\/em>, an influential print and online brand for people living with and affected by HIV\/AIDS.<\/p>\n<p>Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research introduces a groundbreaking long-acting injectable blend of tenofovir, lamivudine, and dolutegravir, proven effective for a month in primate studies. Leveraging cutting-edge nanoparticle technology, this formulation presents an accessible, possibly self-administered solution, marking a significant stride in enhancing HIV treatment and compliance, with particular promise for resource-limited settings.<\/p>\n<p><a href=\"https:\/\/www.poz.com\/article\/longerlasting-hiv-meds-horizon\">https:\/\/www.poz.com\/article\/longerlasting-hiv-meds-horizon<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-2907 size-full\" src=\"https:\/\/depts.washington.edu\/tlcart\/wp-content\/uploads\/94241_poz-logo-TM-tansparent.png_cf8bc221-abab-4ab9-9066-0e5dbf0e9603.png\" alt=\"\" width=\"115\" height=\"54\" \/><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Ho&#8217;s Laboratory is featured on POZ.com, an influential print and online brand for people living with and affected by HIV\/AIDS. Highlighting pivotal developments in HIV treatment from 2023, the article echoes the findings of Perazzolo and colleagues at University of Washington TLC-ART program led by Prfo Ho. Their research introduces a groundbreaking long-acting injectable blend of tenofovir, lamivudine, and dolutegravir, proven effective for a month in primate studies. Leveraging cutting-edge nanoparticle technology, this formulation presents an accessible, possibly self-administered&#8230;<\/p>\n<div><a class=\"more-link\" href=\"https:\/\/depts.washington.edu\/tlcart\/tlc-art-featured-on-poz-com\/\">Continue reading <span class=\"screen-reader-text\">TLC-ART featured on POZ.com<\/span><\/a><\/div>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2905","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/posts\/2905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/comments?post=2905"}],"version-history":[{"count":4,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/posts\/2905\/revisions"}],"predecessor-version":[{"id":2910,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/posts\/2905\/revisions\/2910"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/media?parent=2905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/categories?post=2905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/tlcart\/wp-json\/wp\/v2\/tags?post=2905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}